Enliven Therapeutics logo
Enliven Therapeutics logo

Enliven Therapeutics

enliventherapeutics.com
enliventherapeutics.com • HQ: Boulder, United States • Venture - Series Unknown 2024 • 201-500 employees • Founded 2016 • NASDAQ: ELVN
HQ: Boulder, United States • Venture - Series Unknown 2024 • 201-500 employees • Founded 2016 • NASDAQ: ELVN
Actively hiring
Drug Discovery
Biotechnology
Health Care
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Overview

We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.

People

Helen Collins
Executive Officer
SEC Form D
Benjamin Hohl
Executive Officer
SEC Form D
Anish Patel
Executive Officer
SEC Form D
Joseph Lyssikatos
Executive Officer, Director
SEC Form D
Rahul Ballal
Director
SEC Form D
Samuel Kintz
Executive Officer, Director
SEC Form D
James McArthur
Director
SEC Form D
Christoph Adams
Executive Officer
SEC Form D
Andrew Phillips
Director
SEC Form D
Richard Heyman
Director
SEC Form D
Mika Derynck
Director
SEC Form D
Jake Bauer
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
Boulder United States
HQ
Burlingame United States
Regional office
Anonymous Whistleblower Hotline
205 Park Road, Burlingame, CA 94010
company site

Financials

Total raised
$140.1M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $90M Details
Venture - Series Unknown 2019 $44.1M Details
Venture - Series Unknown 2016 $6M Details